Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: A phase III multicenter randomized trial

Cancer

Volumn 106, Issue 4, 2006, Pages 848-858

  Rifkin, Robert M ^a   Gregory, Stephanie A ^b   Mohrbacher, Ann ^c   Hussein, Mohamad A ^d,e  

^a ROCKY MOUNTAIN CANCER CENTERS   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Dexamethasone; Doxorubicin; Drug resistance; Drug toxicity; Liposomes; Multiple myeloma; Neoplasms; Neutropenic fever; Pegylated liposomal doxorubicin; Vincristine

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; DOXORUBICIN; GROWTH FACTOR; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; STOMATITIS; SYNCOPE; THROMBOEMBOLISM; THROMBOPHLEBITIS; TOXICITY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERIZATION, CENTRAL VENOUS; DEXAMETHASONE; DOXORUBICIN; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 32544446935     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21662     Document Type: Article

References (33)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:2465-2499.
3. Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist. 2003;8(Suppl 3):39-45.
4. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
5. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
6. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2:882-885.
7. Durie BGM, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol. 2004;22:1857-1863.
8. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol. 1989;71:25-30.
9. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer. 2004;100:2052-2063.
10. Blade J, Vesole DH, Gertz M. Transplantation for multiple myeloma: who, when, how often? Blood. 2003;102:3469-3477.
11. Facon T, Mary JY, Attal M, et al. Melphalan-prednisone versus dexamethasone-based regimens for newly diagnosed myeloma patients aged 65-75 years. Safety analysis of the IFM 95 trial on 457 patients [abstract 4609]. Blood. 1999;94:309b.
12. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711-716.
13. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996;36:55-63.
14. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
15. 2. Ann Oncol. 2000;11:1029-1033.
16. Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95:2160-2168.
17. Jackson DV, Case LD, Pope EK, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol. 1985;3:1508-1512.
18. Alexanian R, Balcerzak S, Bonnet JD, et al. Prognostic factors in multiple myeloma. Cancer. 1975;36:1192-1201.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003;14:1039-1044.
21. Baldini L, Radaelli F, Chiorboli O, et al. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer. 1991;68:62-67.
22. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
23. Tsiara SN, Kapsali E, Christou L, Panteli A, Pritsivelis N, Bourantas KL. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol. 2000;65:118-122.
24. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
25. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
26. Rajkumar SV, Blood E, Vesole DH, Shepard R, Greipp PR. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a Phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract 205]. Blood. 2004;104:63a.
27. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. Version 1. Available at URL: http://www.nccn.org/ professionals/physician_gls/PDF/myeloma.pdf (accessed February 9, 2005).
28. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
29. Barlogie B, Rasmussen E, Tricot G, Crowley J. Management of patients with multiple myeloma (MM) failing total therapy 2 (TT 2) according to thalidomide (THAL) randomization [abstract 1483]. Blood. 2004;104:414a.
30. Offidani M, Marconi M, Corvatta L, et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) in elderly/relapsed multiple myeloma (MM) patient [abstract]. Haematologica. 2005;90(Suppl 2):9.
31. Agrawal NR, Hussein MA, Elson P, Karam MA, Reed J, Srkalovic G. Pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients [abstract]. Blood. 2003;102:237a.
32. He XS, Srkalovic G, Hsi ED, Raju R, Elson P, Hussein MA. The effects of different chemotherapeautic regimens on bone marrow microvessel density in patients with multiple myeloma [abstract 2424]. Proc Am Soc Clin Oncol. 2003;22:603.
33. Hussein MR, Elson P, Tsoe EA, Karam M, Srkaloci G. Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM) [abstract 1566]. Blood. 2002;100:403a.